Abstract. microRNAs (miRNAs) are non-coding short nucleotides that exhibit a unique function as translational suppressors towards a wide realm of mRNAs. To date, a specific set of miRNAs has been characterized as oncogenes and tumor suppressors based on their expression levels and/or target mRNA functions; however, a comprehensive view of the changes in miRNA expression regulated by pivotal cellular signaling mechanisms remains elusive. Here, we aimed to characterize common and unique miRNAs regulated by transcriptional regulators such as oncogenic HRAS, c-Jun and E2F family members (E2F1~E2F6) in the human cancer cell lines A549 and HeLa. For this purpose, we employed a miRNA microarray and identified several miRNAs that were commonly regulated by transcriptional regulators. Next we tested whether these miRNAs could affect any of the signal pathways by employing luciferase reporters bearing response elements for various cellular signaling pathways. Among those tested, luciferase reporter bearing interferon Á activation site responsive element was solely activated by miR-494, indicating that the overexpression of miR-494 has a limited effect on a specific signal pathway in A549 cells. Taken together, these results suggest that a unique subset of miRNAs could have an integrating effect on upstream pivotal transcriptional regulators influencing decisions regarding proper cellular responses.
Introduction
The mechanics of cancer biology have been extensively investigated leading to the realization that complex behaviors involving deregulated oncogenes and the functional loss of tumor suppressors are involved. Genes involved in the regulation of signal transduction pathways and transcriptional regulations are recognized as being the most important targets for investigating cancer biology. So far, factors upstream and downstream of mitogen-activated protein (MAP) kinase cascades has been a central issue (1) . RAS is known as a representative upstream regulator of MAP kinase (2) . As major downstream regulators or effectors of MAP kinase, transcription factors such as p53 (3), c-Myc (4), c-Jun (5) and retinoblastoma protein (pRb)/E2F (6) are widely recognized, as their proper regulation could be applied to cancer therapy.
Towards a better understanding of the complex molecular networks that are perturbed by deregulated regulators in tumor specimens, numerous target mRNAs controlled by such regulators have been investigated. Besides mRNAs, the importance of microRNAs (miRNAs) in human disease, especially carcinogenesis, has emerged as another important issue (7) . At present, more than a dozen miRNAs have been characterized as oncogenes and tumor suppressors (8, 9) . As a representative tumor suppressive miRNA, let-7 has been shown to inhibit cell proliferation pathways including RAS (10, 11) . Another tumor suppressor, miR-145, is a p53 target miRNA that directly targets c-Myc for down-regulation (12) . Among the known transcriptional regulators of miRNAs, p53-regulated miRNAs have been investigated intensively (13, 14) . The miR-34 family (a~c) has been recognized as tumor suppressors under the control of p53 (15, 16) . Interestingly, miR-34a overexpression resulted in the downregulation of the E2F pathway and the up-regulation of the p53 pathway (17) , suggesting a possible regulatory pathway between p53 and E2F via miRNAs. E2F1 has been implicated in the transcriptional regulation of miR-106b/93/25 polycistron in a p53-dependent manner (18) . Moreover, miR-449a/b has been shown to act as a direct target of E2F1. In turn, miR449a/b inhibits oncogenic cyclin-dependent kinase 6 (CDK6) and CDC25A, resulting in pRb dephosphorylation and thus constituting a negative feedback loop towards the pRb/E2F1 pathway (19) . On the other hand, the miR-17-92 oncogene cluster, which is comprised of miR-17-5p and miR-20a, has been shown to be regulated by c-Myc. These miRNAs inhibit the E2F1 activity (20, 21) . E2F1, the translation of E2F2 and E2F3, has also been proven to be suppressed by miR-20a, and E2F1~E2F3 were capable of binding to the promoter of miR-17-92 cluster (22, 23) . Transcription from the miR-17-92 ONCOLOGY REPORTS 24: 1371 -1381 cluster has shown to be repressed by p53 under hypoxic conditions (24) .
Oncogenic and anti-oncogenic signaling stemming from p53, c-Myc and E2F1 are integrated by specific miRNA species, thus establishing positive and negative feedback regulation (25) (26) (27) (28) . Accumulating evidence indicates that miRNA expression patterns produced by an miRNA microarray analyses can be applied to cancer diagnosis because the miRNA expression pattern is strongly correlated with the cancer stage and cancer cell type (29, 30) .
Here, we focused on the profiling of miRNAs that are regulated by pivotal transcriptional regulators in the human cancer cell lines A549 and HeLa. As p53 and c-Myc target miRNAs have been widely reported (31), we selected c-Jun and E2F family members E2F1~E2F6 and their upstream regulator oncogenic HRAS. Although the miR-155 promoter is known to be regulated by activator protein 1 (AP1) containing c-Jun as a heterodimeric protein (32), c-Jundependent regulation of miRNAs is not fully understood. In addition, the differential miRNA transcriptional regulation by E2F family members is still unclear. Our studies illuminate that the mechanism underlying the transcriptional switch regulated by pivotal transcription factors could be integrated into a specific subset of miRNAs in a cell-type specific manner.
Materials and methods

Cells, RNAs and plasmids. A549 (human lung cancer cells)
and HeLa (human cervical cancer cells) were cultured in Earle's modified Eagle's medium (MEM) supplemented with 1% non-essential amino acids, antibiotic-antimycotics (all from Invitrogen, Carlsbad, CA), and 10% fetal bovine serum (FBS). Hereafter complete medium is referred to as MEM. miScript miRNA Mimic (Syn-hsa-miR-483-5p and Synhsa-miR-494) and miScript miRNA Inhibitor (anti-hsa-miR-139-3p) were purchased from Qiagen (Valencia, CA) as synthesized, double-stranded RNA. The sequences were as follows: Syn-hsa-miR-483-5p, AAGACGGGAGGAAAGAA GGGAG (Cat. no. MSY0004761); Syn-hsa-miR-494, UGA AACAUACACGGGAAACCUC (Cat. no. MSY0002816), and anti-hsa-miR-139-3p, GGAGACGCGGCCCUGUUGG AGU (Cat. no. MIN0004552). The Sanger miRBase accession numbers for the stem-loop sequences were MI0002467 (official symbol MIR483; hsa-mir-483) and MI0003134 (official symbol MIR494; hsa-mir-494), while those for the mature sequences were MIMAT0004761 (hsa-miR-483-5p) and MIMAT0002816 (hsa-miR-494). The Stealth RNA interference Negative Control Duplexes (High GC Duplex) was purchased from Invitrogen and used as a control.
To construct the pGL3-Promoter (Promega, Madison, WI) reporter using a miRNA target site in the 3' untranslated region (3'UTR) of the luciferase gene, the following sense and antisense sequences were synthesized and annealed: pGL3-Promoter-483-5p, GCTCTAGAGAATTCCTCCCTTC TTTCCTCCCGTCTTTCTAGAGC and GCTCTAGAAAG ACGGGAGGAAAGAAGGGAGGAATTCTCTAGAGC; and pGL3-Promoter-494, GCTCTAGAGAATTCGAGGTTT CCCGTGTATGTTTCATCTAGAGC and GCTCTAGATG AAACATACACGGGAAACCTCGAATTCTCTAGAGC (XbaI sites are underlined and EcoRI sites are italicized). Annealed oligonucleotides were digested with XbaI and inserted into the XbaI site of the pGL3-Promoter. EcoRI digestion to check the existence of the inserted fragments and sequencing with the RV4 primer were performed. The expression vectors encoding HRAS (V12), c-Jun and E2F1~E2F6 were previously described (33) (34) (35) . pcDNA3 was purchased from Invitrogen.
Transfection and luciferase reporter assay. Cells were transfected with Lipofectamine Plus transfection reagent (Invitrogen) according to the manufacturer's instruction. Briefly, 3x10 5 cells were inoculated into a 6-well plate the day before transfection. Plasmid DNA (0.5-2 μg per well) mixed with transfection reagent was directly added to the cell cultures. After 48 h of transfection, the total RNA and cell lysates were recovered for microarray and Western blotting, respectively.
For miRNAs, transfection was performed using the HiPerFect transfection reagent (Qiagen), according to the manufacturer's instructions. The cells were plated into a 24-well dish 24 h prior to transfection (3x10 4 cells/well). Briefly, 12 pmol (0.6 μl of 20 μM stock) RNA and 3 μl of transfection reagent were incubated in 100 μl of MEM without FBS for 10 min to facilitate complex formation at room temperature. The resulting mixture was added to the cells cultured in 500 μl of MEM. After 24 h, pGL3-Promoter-based luciferase reporters (400 ng) or pTA-Luc (bearing response elements for E2F, Myc, p53, pRb, NFAT, STAT3, ISRE and GAS)/pTAL-Luc (bearing response elements for AP1, CRE, GRE, HSE, NF-κB and SRE) reporter series (all purchased from Clontech) (200 ng) were transfected with FuGENE6 transfection reagent (Roche, Basel, Switzerland), in accordance with the manufacturer's instructions. Briefly, firefly luciferase reporter plasmid and 0.6 ng of the Renilla luciferase reporter plasmid (pRL-TK; Promega) per 24-well dish were used for each transfection. The cells were lysed at 24 h after transfection by applying 100 μl of Passive Lysis Buffer from the Dual Luciferase Reporter Assay kit (Promega) into each well of the 24-well plate. For E2F1 expression vector and pGL3-Promoter-based luciferase reporters co-transfection, cells were lysed at 72 h after transfection. Five microliters of cell lysate was used for the luciferase reporter assay with the same kit according to the manufacturer's protocol. Light intensity was quantified using a GloMax 20/20n Luminometer (Promega). Experiments were performed at least in triplicate. As a control for transfection efficiency, the firefly luciferase activity values were normalized to the Renilla luciferase activity values. Data are presented as the mean values ± SD (standard deviation). Statistical differences were analyzed using the Student's t-test. A value of P<0.05 (n=3) was considered to indicate a statistically significant difference.
miRNA microarray analysis. After 48 h of plasmid transfection, total RNA was extracted using TRIzol reagent (Invitrogen), according to the manufacturer's instructions. The integrity of the RNA was checked using electrophoresis (Agilent 2100 Bioanalyzer; Agilent Technologies, Inc., Santa Clara, CA). The procedure for the microarray analysis (n=1) using the human miRNA Microarray kit Ver.2, which covered 723 mature and 76 viral miRNAs, was based on the Agilent Technologies protocol (http://www.chem.agilent.com). Briefly, 100 ng of total RNA was dephosphorylated using calf intestine alkaline phosphatase (GE Healthcare, Waukesha, WI), heat-denatured with dimethyl sulfoxide (DMSO) and labeled with T4 RNA ligase (GE Healthcare). After column purification, hybridization and washing were performed using an miRNA Labeling Reagent and Hybridization kit (Agilent) and Gene Expression Wash Pack (Agilent) according to the manufacturer's protocol. Array scanning was performed using a DNA MicroArray Scanner (Agilent). Spot analysis for digitalization of the hybridization images was performed using Feature Extraction Ver.9.5.3 (Agilent) and was compared with the control using GeneSpring GX (Agilent), according to manufacturer's standard manual. Gene expression changes over and under 1.5-fold were extracted and used for further analyses. Signals with present/present for test sample/control were selected for further data analysis. For the miRNA annotation, the authors referred to miRBase (http://www.mirbase.org/) (36) .
Western blot analysis. Western blotting was performed using a previously reported method (33) . A total of 20-40 μg of cell lysates were used per lane. The following antibodies were used: HRAS (sc-520), E2F1 (sc-193), E2F2 (sc-633), E2F3 (sc-879), E2F4 (sc-866), E2F5 (sc-968) and E2F6 (sc-22823) (all from Santa Cruz Biotechnology, Santa Cruz, CA). Antic-Jun (60A8) was purchased from Cell Signaling Technology (Beverley, MA). Anti-GAPDH was purchased from Applied Biosystems (Foster City, CA).
TaqMan quantitative RT-PCR. RNA (100 ng) was reversetranscribed using specific miRNA stem-loop primers and the TaqMan miRNA reverse transcription kit (Applied Biosystems). Mature miRNA expression was measured with TaqMan microRNA assays (Applied Biosystems) according to the manufacturer's instructions. PCR mixtures included the TaqMan microRNA Assay primer for human miRNAs and TaqMan Universal PCR Master Mix in a total reaction volume of 20 μl. Reactions were performed with the 9600 emulation (Default) program on a 7500 Fast Real-Time PCR System (Applied Biosystems). Cycling parameters were 95˚C for 10 min and then 40 cycles of 95˚C for 15 sec, annealed/ extended at 60˚C for 1 min. The cycle threshold (Ct) values, corresponding to the PCR cycle number at which fluorescence emission reaches a threshold above baseline emission, were determined, and miRNA expression values were calculated using RNU6B as endogenous control (Applied Biosystems) following the comparative Ct (ΔΔCt) method. All reactions were performed in triplicate. Results were expressed relative to the control empty vector pcDNA3-transfected cells and arbitrarily assigned a value of 1.
Results
Comprehensive analysis of miRNAs regulated by pivotal transcriptional regulators.
Identifying and characterizing which miRNAs are regulated by major transcriptional regulators is an intriguing task. As transcriptional regulators, we selected oncogenic HRAS (V12) (37) and c-Jun; activator E2Fs (E2F1~E2F3); and repressor E2Fs (E2F4~E2F6). Expression vectors encoding each cDNA were transiently overexpressed in the widely used cancer cell lines A549 and HeLa. After 48 h of transfection, the expression level of each protein was detected using Western blotting (Fig. 1) . Next, the miRNA signatures were determined using an miRNA microarray, and the up-and down-regulated miRNAs were tabulated (Tables I  and II) . Significantly, characteristic subsets of miRNAs were coordinately regulated by different transcriptional regulators. As summarized in Fig. 2A , in A549 cells, miR-483-5p was upregulated by activator E2Fs and miR-494 was up-regulated by HRAS, c-Jun, E2F1, E2F3 and E2F6. Similarly, miR-345 was up-regulated by HRAS, c-Jun, E2F1 and E2F3 but downregulated by E2F5 and E2F6. The miR-135a * was also upregulated by HRAS, c-Jun, E2F1 and E2F3. The miR-139-3p was down-regulated by repressor E2Fs. In HeLa cells, as shown in Fig. 2B , a dozen of miRNAs were commonly but intricately regulated by transcriptional regulators. For instance, miR-26b, let-7a, let-7f and let-7g were up-regulated by E2F1 and repressor E2Fs and miR-638, miR-940 and miR-125a-3p were down-regulated by E2F1 and repressor E2Fs. Both miR-29b and miR-221 were down-regulated by activator E2Fs. On the other hand, an array of miRNAs was exclusively downregulated by repressor E2Fs. Several miRNAs were regulated by at least two transcriptional regulators in A549 and HeLa cells (Fig. 2C) . For example, miR-483-5p was up-regulated by E2F2 and E2F3 and miR-494 was up-regulated by c-Jun and E2F3. In contrast, miR-139-3p was exclusively downregulated by repressor E2Fs and miR-370 was downregulated by E2F5 and E2F6. The miR-483-5p is localized to chromosome 11p15.5 within the intron of insulin-like growth factor 2 (IGF2, alias somatomedin A), whereas miR-494 and miR-345 are localized to an intergenic region. The orientation of transcription between miR-483-5p and IGF2 is the same. We tested whether the expressions of miR-483-5p and IGF2 were coordinated. Reverse transcription (RT)-PCR analysis revealed that the overexpression of E2F1 in A549 cells resulted in the upregulation of IGF2 mRNA (data not shown).
To ascertain the reproducibility of the miRNA expression profile obtained by the miRNA microarray analysis, we examined their expression levels by using a TaqMan real- Table I . Up-and down-regulation of miRNAs by HRAS, c-Jun and E2F1~E2F6 in A549 cells. Table I . Continued. Table II . Up-and down-regulation of miRNAs by HRAS, c-Jun and E2F1~E2F6 in HeLa cells. (Fig. 2D ).
-------------------------------------------------
-------------------------------------------------Ratio -------------------------------------------------
Silencing effect of miR-483-5p and miR-494.
The miRNAmediated suppression of translation from target mRNA is known to occur through a complementarity to the 3'UTR of the target mRNA (38) . We validated the effects of miR-483-5p and miR-494 on the luciferase gene reporter, which possesses the miRNA target sequence in the 3'UTR. For this purpose, synthesized mature miRNAs were introduced into A549 cells, and 24 h thereafter, luciferase reporter was transfected. Both miR-483-5p and miR-494 successfully down-regulated their own target sequence bearing the luciferase reporter, compared with control RNA (Fig. 3A and B Among the elements that were tested, only the activity of the GAS (interferon Á activation site) reporter was increased 2-fold by miR-494, compared with that of the control (Fig. 3E) , suggesting that miR-494 might target the inhibitor(s) of JAK (janus kinases)/STAT (signal transducers and activators of transcription) signaling upstream of the GAS element. The miR-483-5p and miR-139-3p inhibitor showed no effect on the reporters that were tested (data not shown).
Discussion
How miRNAs are deregulated through signal transduction pathways during carcinogenesis is a major concern (39). Here, we investigated the mammalian cell proliferation control network, consisting of the transcriptional regulators HRAS, c-Jun and E2F1~E2F6, to seek an answer to the above question. Tiny, mature miRNAs can negatively regulate specific target mRNAs by translational inhibition or mRNA degradation (7) . The expression levels of miRNAs are well correlated with the etiology of carcinogenesis (8, 9) . In this study, we revealed that transcriptional regulators uniquely control a characteristic subset of miRNA in a cell-specific manner. Among them, we noted that miR-483-5p, miR-494, miR-345, miR-139-3p and miR-370 might serve as potential diagnostic markers of carcinogenesis. So far, several reports on these miRNAs are available as discussed in more detail below. An expression profiling-based analysis revealed that miR-483-5p is up-regulated in malignant adrenocortical tumors, compared with in benign ones, indicating that the upregulation of miR-483-5p might be associated with a poorer cancer-specific survival (40) . miR-494 was first reported as part of a miRNA expression profile for retinoblastoma, belonging to a cluster of highly expressed miRNAs (41) . Recently, in a cultured primary bronchial epithelial cell system exposed to benzo[a]pyrene, miR-494 expression was upregulated in parallel with the down-regulated expression of CDK6 (42) . miR-494 also decreased PTEN (phosphatase and tensin homolog) protein and reportedly functions as an oncogene in primary bronchial epithelial cell carcinogenesis (43) . Based on the elevated expression of miR-494 in pRbinactivated cells, it is highly possible that deregulated E2F might activate miR-494 expression. This notion agrees well with our present results. PTEN and CDK6 are in silico targets of miR-494, as easily predicted by TargetScan 5.0 (http://www. targetscan.org/). One reason explaining why miR-494 only activated the GAS reporter in the present study is that while PTEN might indeed be a direct target of miR-494, it failed to modulate any of the signaling pathways examined in the present assay. Probably, the down-regulation of CDK6 induced by miR-494 in A549 cells was too small to modulate the activity of the reporters. miRNAs are known to have multiple target genes (44) . Therefore, it is rather surprising that miR-494 only affected the signaling pathway represented by the GAS element (45) . Intriguingly, miR-494 did not have any effect Table II . Continued. 0.67 on the ISRE, indicating that miR-494 affected a signaling molecule specifically involved in GAS but not in ISRE signaling. p38 MAP kinase is known to be essential for gene transcription via the GAS element (46) . Indeed, miR-494 is up-regulated by HRAS in A549 cells. A more detailed analysis of how HRAS, c-Jun and E2Fs-activated miR-494 is involved in the regulation of cytokine-induced gene expression should be defined in the context of immune-related cell system, especially with regard to the JAK/STAT signaling pathways (47) . Consequently, the current approach employing reporters with various elements for signaling pathways might not be sufficient to detect down-regulated targets.
miRNA profiling using a miRNA microarray revealed that miR-345 was highly expressed in malignant mesothelioma, compared with normal mesothelium (48) . Expression profiling revealed that an increase in miR-345 expression was consistently observed during the progression of oral leuko- plakia lesions into oral squamous cell carcinoma (49) . Interestingly, miR-345 was also found to be the most significantly dysregulated miRNA in cisplatin-resistant MCF-7 human breast adenocarcinoma cells and to target the human multidrug resistance-associated protein 1 (MRP1) (50) .
Based on evidence from previous reports, miR-483-5p, miR-494 and miR-345 can all be considered as oncogenes. Our present results also support this notion. A comparison between A549 (p53 wild-type) and HeLa [with p53 silenced by HPV (human papillomavirus) genome integration] cells revealed that the miRNA expression patterns were not necessarily conserved, but were partially matched. These results suggest that the p53 status might be responsible for the miRNA signature regulated by transcription factors such as E2F and c-Jun as well as c-Myc. Needless to say, functional studies are needed to explain how these commonly regulated miRNAs can control cellular phenotypes in certain cells. Among the reported E2F1-regulated miRNAs, miR-17-92 cluster (miR-17-5p, miR- 17-3p, miR-18a, miR-19a, miR-19b-1, miR-20a and miR-92-1) were not detected in the present study (22, 23) except for down-regulation of miR-18a and miR-19a by E2F3 in HeLa cells. This discrepancy probably be due to the differences of cell types tested and expression systems for E2F1 (22, 23) . For example, E2F1-inducible Saos-2 cell line where E2F1 is fused to the estrogen receptor-binding domain was used to identify miR-449a/b as novel E2F1-inducible targets (19) . These miRNAs were not detected in the present study. In contrast, in E2F1/3-knockout cells, miRNA clusters including let-7a-d and let-7i were identified as direct targets of E2F1 and E2F3 (51) . In the present study, let-7a, let-7f and let-7g were up-regulated by E2F1 and E2F4~6 in HeLa cells. In addition, let-7b was up-regulated by E2F3 and E2F6, and let-7c and let-7d were up-regulated by E2F4~6, and let-7e was up-regulated by E2F5 and E2F6, and let-7i was upregulated by E2F4 and E2F5 in HeLa cells. Conversely, let-7d and let-7e were down-regulated by E2F3 in A549 cells. As well miR-17-92 cluster, miR-106b-25 cluster has been shown to be regulated by E2F1 (18) . Notably, miR-25 was solely up-regulated by E2F4~6 in HeLa cells but not in A549 cells. Collectively, comprehensive analysis of cell type-specific miRNAs expression regulated by various transcription factors enables us to select unique and common miRNAs that can be utilized as disease specific biomarkers for prognosis, diagnosis and therapeutics.
Direct introduction of synthetic mature miRNAs clearly suppressed the activities of luciferase gene reporters, which possesses miRNAs responsive sequences in the 3'UTR of luciferase gene. Contrary to this, ectopic expression of E2F1 failed to modulate the activities of these luciferase gene reporters. This can be explained by the fact that the amounts of synthetic mature miRNAs are overwhelming when compared to those of endogenous miRNAs induced by E2F1. Alternatively, within 72 h of assay interval, secondary effects of E2F1 may be occurred. Indeed, E2F1 has been shown to be involved in the complex gene network (28) .
In conclusion, we identified miR-483-5p, miR-494, miR-345, miR-139-3p and miR-370 as comprising a unique subset of miRNAs located downstream of pivotal transcription factors in A549 and HeLa cells. We believe that the present miRNA profiling results contribute to a unique aspect of the miRNA regulation that is involved in the complex gene regulatory network of cancerous cells.
